KERX up +1.71% percent Today $KERX High is at 15.68 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2014 at 2:50 PM

KERX up +1.71% percent Today $KERX High is at 15.68 and the Low 15.41 with current volume of 303,422.

Recent News posted below.

Keryx Biopharmaceuticals KERX other info.
http://investorshangout.com/Keryx-Biopharmace...ERX-54563/

KERX Keryx Biopharmaceuticals Recent Headline News

Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST

OCN: 21.28 (+0.68), KOS: 9.50 (-0.16), KIN: 8.94 (+0.20), VSAT: 66.21 (-1.40), RFMD: 13.49 (-0.08), EBAY: 54.87 (+0.51), TQNT: 22.45 (-0.15), IDIX: 24.50 (+0.05), SEMI: 17.01 (-0.42), VRTV: 47.17 (+1.02), THRX: 13.25 (+0.02), TBPH: 17.37 (-0.11), IMOS: 21.13 (-0.76), ELOS: 9.95 (-0.34), MU: 32.28 (-0.34), AR: 52.66 (+0.15), NCQ: 0.71 (+0.02), PBF: 27.54 (+0.45), LNG: 72.19 (+0.33), ATRA: 24.43 (+1.26), KERX: 15.21 (unch), NG: 2.92 (+0.04), AOI: 1.85 (unch), FWP: 21.80 (-0.59), BYD: 11.64 (-0.42), ALDW: 17.38 (+0.25), SUNE: 16.50 (-0.43), MRK: 59.51 (+0.44), AVEO: 0.98 (+0.04), AIG: 53.98 (+0.08)

Keryx Bio presents Ferric Citrate safety data at ASN meeting
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 7:01AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
GlobeNewswire - Sat Nov 15, 9:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company"

today announced results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The OLE findings were presented as a late-breaking poster (Abstract #SA-PO1102) at the 2014 American Society of Nephrology's (ASN) Kidney Week meeting in Philadelphia, PA. The results are consistent with those seen in the pivotal Phase 3 trial.
KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. to Present at the Stifel 2014 Healthcare Conference
GlobeNewswire - Fri Nov 14, 7:30AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present a corporate overview at the Stifel 2014 Healthcare Conference taking place November 18-19 in New York City.
KERX: 15.21 (unch)

'Mad Money' Lightning Round: Intel Is Underrated by Wall Street
at The Street - Tue Nov 11, 5:00AM CST
Cramer doesn't think now is a good time for Caterpillar.
KMI: 40.35 (+0.98), GD: 142.21 (-0.45), LMT: 185.52 (-1.08), RTN: 103.14 (-1.49), DDD: 35.60 (+1.53), NOC: 135.83 (-0.24), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), GM: 32.49 (+0.70), PG: 87.52 (-0.59), CAT: 101.95 (+0.61)

Cramer's Lightning Round - I Curse The Day I Bought General Motors (11/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Tue Nov 11, 3:18AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday November 10. Bullish Calls: Merck (NYSE: MRK ): Cramer prefers Merck to Procter & Gamble. Intel (NASDAQ: INTC ): "INTC is underrated...
GD: 142.21 (-0.45), LMT: 185.52 (-1.08), NOC: 135.83 (-0.24), DDD: 35.60 (+1.53), MO: 49.09 (+0.31), INTC: 34.17 (+0.22), HPQ: 37.41 (+0.49), KERX: 15.21 (unch), WPRT: 5.79 (-0.08), IBM: 164.59 (+0.43), MRK: 59.51 (+0.44), SSYS: 105.06 (+0.21), GM: 32.49 (+0.70), CAT: 101.95 (+0.61), LINE: 22.24 (-0.41), PG: 87.52 (-0.59)

Keryx (KERX) in Focus: Stock Adds 11.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:46AM CST
Keryx (KERX) was a big mover last session, with shares rising nearly 12% on the day.
AGEN: 2.97 (-0.01), BIIB: 305.00 (-0.43), AMAG: 35.05 (+1.05), KERX: 15.21 (unch)

Nasdaq stocks posting largest percentage increases
AP - Thu Nov 06, 12:17PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ESYS: 17.33 (+0.01), SWIR: 38.56 (+0.25), PERI: 5.79 (+0.12), JIVE: 6.53 (-0.30), TREE: 46.55 (-0.85), KERX: 15.21 (unch), ECYT: 6.57 (+0.15), ADEP: 8.50 (-0.09), ABTL: 10.84 (-0.48), NDLS: 23.21 (-0.27), BSFT: 26.71 (-0.79), SW.TO: 43.62 (+0.45), CALD: 15.83 (-0.23), PLNR: 7.04 (+0.35)

Keryx's (KERX) CEO Ron Bentsur on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 11:50AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals (KERX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST

KERX: 15.21 (unch)

Keryx Biopharma misses Street 3Q forecasts
Automated Insights - Thu Nov 06, 6:36AM CST
NEW YORK (AP) _ Keryx Biopharmaceuticals Inc. (KERX) on Thursday reported a third-quarter loss of $35.3 million.
KERX: 15.21 (unch)

Keryx Biopharmaceuticals EPS of -$0.38
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:04AM CST

KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. Announces Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Thu Nov 06, 6:00AM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company" or "Keryx"

, today announced its financial results for the third quarter ended September 30, 2014. At September 30, 2014, the Company had cash, cash equivalents, interest receivable and investment securities of $118.4 million, as compared to $55.7 million at December 31, 2013.
KERX: 15.21 (unch)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 4:30PM CST

CYNI: 2.71 (-0.04), AAP: 145.78 (+0.97), DNOW: 28.50 (+0.16), AAON: 20.48 (-0.48), CNQ: 35.74 (-0.26), HSP: 58.36 (+0.08), CNK: 35.63 (-0.03), AMSC: 0.98 (-0.05), AES: 13.71 (+0.24), MWIV: 157.95 (+2.90), BBG: 12.95 (-1.16), HZNP: 12.52 (+0.27), KATE: 28.87 (-0.06), MITL: 10.24 (+0.12), AEE: 43.04 (+0.83), HSIC: 130.63 (+0.48), HII: 107.98 (+0.13), NAVB: 1.26 (+0.10), CECE: 14.08 (-0.46), AKRX: 37.88 (-0.33), COTY: 19.02 (-0.13), GOLD: 69.25 (+0.50), IT: 86.06 (+0.01), HNR: 2.89 (-0.10), KERX: 15.21 (unch), CECO: 5.69 (-0.20), HSC: 19.94 (+0.44), AMRC: 8.03 (-0.06), KLIC: 13.80 (-0.16), GEO: 39.30 (-0.62), AINV: 8.18 (-0.01), BCE: 47.39 (+0.52), AZN: 72.44 (-0.41), BCRX: 10.21 (+0.14), CPN: 23.45 (-0.15), BR: 45.10 (+0.03), FUR: 16.96 (+0.11), LIN: 24.00 (-0.04), LMIA: 13.88 (+0.16), CDW: 32.81 (-0.14), CVC: 18.70 (+0.16), AAWW: 41.26 (-0.35), GNRC: 41.92 (+0.05), MPEL: 25.99 (-0.54), DTV: 86.99 (-0.56), APA: 72.41 (-0.94), CRZO: 50.25 (-1.34), BKCC: 8.94 (unch), ERJ: 36.95 (+0.19), AMCX: 62.38 (+0.52), LPI: 17.15 (-0.56), HAIN: 108.29 (+0.02), FSYS: 10.03 (-0.38), GLP: 43.39 (+1.09), AOL: 46.57 (+0.53), FUN: 46.74 (-0.12), BDBD: 9.81 (+0.14)

Will Keryx Biopharmaceuticals (KERX) Post Wider Q3 Loss? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:35PM CST
Keryx Biopharmaceuticals, Inc.'s (KERX) is scheduled to report its third-quarter 2014 results on Nov 6.
MNK: 88.24 (+0.13), ACT: 245.62 (+1.85), HSP: 58.36 (+0.08), KERX: 15.21 (unch)

Keryx Biopharmaceuticals Up 9.7% Since SmarTrend Uptrend Call (KERX)
Comtex SmarTrend(R) - Mon Nov 03, 11:18AM CST
SmarTrend identified an Uptrend for Keryx Biopharmaceuticals (NASDAQ:KERX) on October 2nd, 2014 at $15.03. In approximately 1 month, Keryx Biopharmaceuticals has returned 9.68% as of today's recent price of $16.48.
KERX: 15.21 (unch)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 101.03 (-1.03), CLVS: 53.98 (-0.91), ARWR: 5.92 (-0.12), ACHN: 13.25 (-0.72), MRK: 59.51 (+0.44), RTRX: 9.45 (-0.45), RGLS: 16.80 (-0.40), EPZM: 22.68 (-0.29), AGIO: 84.96 (+0.90), RMTI: 10.55 (+0.03), ARNA: 4.53 (unch), KERX: 15.21 (unch)

Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2014 Financial Results
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease, today announced that a conference call will be held on Thursday, November 6, 2014 at 8:00 a.m. ET to discuss results for the third quarter of 2014 and provide an update on the business.
KERX: 15.21 (unch)

Big Board Biotech Stocks in Play This Week
ACCESSWIRE - Tue Oct 28, 1:16PM CDT
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
PACB: 7.04 (+0.24), CYTR: 2.78 (-0.01), KERX: 15.21 (unch)

Keryx Biopharmaceuticals Inc. (KERX) Stock Research Links

KERX Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bamboo Unveils Tailored Home Insurance for Texans

Adapt or Get Left Behind: The Texas Insurance Scene In a world where costs are ballooning and the pressure on the wallet grows heavier, here comes Bamboo Insurance swinging into Texas like a hopeful knight. This plucky insurer is rolling out the Texas Essential Homeowner Program, a highly adaptable, admitted policy that promises to put some power back into the hands of...

Orbis Celebrates 20 Years of Eye Care in Macau

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

LIV Golf's Big Play: Restructuring with Saudi PIF

Trailblazing Change in the Golf World It's like watching a high-stakes game of chess where pieces are worth billions. White Knight Capital Corp. has thrown its hat into the ring with the Public Investment Fund of Saudi Arabia to overhaul LIV Golf Enterprises. This isn't your average Monday morning golf chat; it's full-on corporate drama with financial steroids. Debt Swap...

Halloween 2026: Gemmy's Animatronics Add Thrills

Halloween's New Twist with Gemmy's Animatronics Well, just when you thought Halloween couldn't get any more over the top, here comes Gemmy with their 3-foot tall animatronic characters ready to give your trick-or-treat scene that extra jolt. These aren't just any run-of-the-mill decorations. Nope, they come with a twist—an industrial-strength twist of scares and sweets...

Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

Hartford Students Get Boost from Hygiene Initiatives

Beyond Backpacks: Essential Hygiene for Hartford Kids When September rolls around, it’s not just about those shiny new backpacks and unopened notebooks. In good ol’ Hartford, some students find themselves in need of basics that get overlooked—a stick of deodorant, a bar of soap, maybe some period products. Skimp on these, and all of a sudden, showing up for school...

AI Platform Suno Sued for Exploiting Artists' Identities

AI and the Music Business: A Legal Storm Brews Well, it looks like the music world’s hitting a rough patch with AI in the crosshairs. We've got Korein Tillery, a heavyweight in the legal arena, throwing down the gauntlet against Suno, an AI music-generation platform. Folks, welcome to the battleground where art meets tech and identity theft takes a whole new meaning....

Chris Auffenberg Buick: 1.9% APR Drives New Deals

New Financing Options in Carbondale In a world where financing a car sometimes feels like predicting the weather—unreliable and erratic—Chris Auffenberg Buick is turning the tables down in Carbondale with a refreshing approach. They're trotting out a 1.9% APR financing option for those Buick lovers who qualify, all through GM Financial. It's the kind of deal that...

Inturai Ventures Closes Final Tranche with a Twist

Wrapping Up a Wild Ride in the Investment Arena Markets are a fickle friend, and today we've got Inturai Ventures calling it a day on their latest cash grab. They've locked the final tranche of their private placement, pulling in an aggregate $963,713.70. Feels like they're counting pennies in this venture, but every cent counts when your aim is to shake up industries...

Delisting Gray Wolf Sparks Heated Hunter Nation Debate

Unraveling the Gray Wolf Controversy What are we looking at here—political maneuvering wrapped in a fur coat? Trump's executive order is making some calls I didn’t see coming. By pushing to delist the gray wolf from the Endangered Species Act (ESA), he's stirring up a mix of joy, outrage, and a boatload of debate about environmental ethics, conservation priorities,...